Essayer OR - Gratuit
Crucial to see who’s driving the share prices, says McKinsey’s Koller
Mint Mumbai
|December 08, 2025
"I don't know, and it is hard to say,” says Tim Koller when asked about the possibility of a ninth edition of Valuation, the celebrated book he coauthored with Marc Goedhart and David Wessels.
Now in its eighth edition, the 952-page volume has become a staple in boardrooms and business schools alike, shaping how corporate leaders think about value creation, and has sold over 1 million copies worldwide—a rare feat for a corporate finance text.
As he approaches retirement from McKinsey & Co. in February, Koller hopes his colleagues will continue championing what he sees as the core of sound decision-making: pursuing growth only when it delivers strong and sustainable returns on capital.
In a conversation with Mint, the valuation expert reflects on heated equity markets, the rise of retail investing and the myths that still cloud our understanding of performance, while reminding companies that long-term value still depends on fundamentals, not momentum. Company leadership should pursue the “right balance” between ‘growth and return on capital’ to drive valuation, he says, adding that profits must be sustainable and capital must be allocated and reallocated to strategic growth opportunities. Edited excerpts from the interview:
This is also compounded by the fact that smart investors are selling their stakes in these startups, whereas small investors are buying in. Do you foresee a scenario where the small investors will hold the can?
The most crucial thing to look at is who's driving the share prices. If you look at the mega seven companies in the US, you'll see that the percentage of shares owned by retail investors is about double that of most companies. So, the share prices are being driven by relatively unsophisticated investors. And so that's when you have to be cautious.
Cette histoire est tirée de l'édition December 08, 2025 de Mint Mumbai.
Abonnez-vous à Magzter GOLD pour accéder à des milliers d'histoires premium sélectionnées et à plus de 9 000 magazines et journaux.
Déjà abonné ? Se connecter
PLUS D'HISTOIRES DE Mint Mumbai
Mint Mumbai
Anju Dodiya creates disquieting worlds
Artist Anju Dodiya discusses the ideas, influences and inspiration behind her new solo show, 'The Geometry of Ash'
5 mins
December 13, 2025
Mint Mumbai
English's place in history is not black and white
In 1784, two white men joined forces to establish an English school in Thanjavur, Tamil Nadu.
4 mins
December 13, 2025
Mint Mumbai
Rising costs force Indian firms to rewrite employee benefits
Indian companies are rethinking the benefits they offer their staff, such as healthcare, retiral plans, well-being perks, and leave, as they seek to control budgets while retaining top talent without compromising on employee experience.
3 mins
December 13, 2025
Mint Mumbai
A modern-day throwback to 'Malgudi Days'
Sita Bhaskar's latest novel revisits writer R.K. Narayan’s legacy to explore class, caste, and community in Mysuru
3 mins
December 13, 2025
Mint Mumbai
Rajasthan limits e-NAM 2.0 pilot amid snags; 1.0 to stay
The Centre restricted e-NAM 2.0 pilot to 10 mandis, including Tonk, Jodhpur and Sujangarh
3 mins
December 13, 2025
Mint Mumbai
IiAS puts Bhatia, IndiGo board under the scanner
Institutional Investor Advisory Services India Ltd (IiAS) has faulted IndiGo promoter and managing director (MD) Rahul Bhatia for not leading from the front when the airline is facing its most challenging operational episode, even as it has sought a review of the current board structure which allows him to nominate half of the board.
2 mins
December 13, 2025
Mint Mumbai
Govt’s insurance reform allows 100% FDI, composite licences
The government has paved the way for 100% foreign direct investment in the insurance sector, composite licences and easier capital requirements, among others sweeping reforms, as the Union cabinet cleared the enabling legislation, said two officials aware of the matter.
3 mins
December 13, 2025
Mint Mumbai
Novo Nordisk debuts Ozempic at ₹2,200 a week
Danish drugmaker Novo Nordisk on Friday launched its blockbuster diabetes drug Ozempic in India, with a starting price of ₹2,200 per week.
3 mins
December 13, 2025
Mint Mumbai
CBDC safer option, stablecoins pose greater risk: RBI
Central bank digital currencies are a far safer option than stablecoins, which pose greater risks than their purported benefits, according to Reserve Bank of India (RBI) deputy governor T. Rabi Sankar.
2 mins
December 13, 2025
Mint Mumbai
Sebi weighs easier unified penalty rules for listed cos
Explores framework like the one for brokers that standardized and reduced fines
3 mins
December 13, 2025
Listen
Translate
Change font size
